GB2448153A - Coated Implantable Medical Devices - Google Patents

Coated Implantable Medical Devices Download PDF

Info

Publication number
GB2448153A
GB2448153A GB0706532A GB0706532A GB2448153A GB 2448153 A GB2448153 A GB 2448153A GB 0706532 A GB0706532 A GB 0706532A GB 0706532 A GB0706532 A GB 0706532A GB 2448153 A GB2448153 A GB 2448153A
Authority
GB
Grant status
Application
Patent type
Prior art keywords
stent
device according
coating
drug
device
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB0706532A
Other versions
GB2448153B (en )
GB0706532D0 (en )
Inventor
Gerhard Anthony Symons
David Robert Hampton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CAMSTENT Ltd MBE
Original Assignee
Camstent Ltd Mbe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L17/00Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/005Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L17/00Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/14Post-treatment to improve physical properties
    • A61L17/145Coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28Materials for coating prostheses
    • A61L27/34Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08Materials for coatings
    • A61L29/085Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406Antibiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42Anti-thrombotic agents, anticoagulants, anti-platelet agents

Abstract

Coated implantable medical devices where the surface can be both hydrophobic and oleophobic. Device such as catheter, vascular graft, cardiac pacer lead, heart diaphragm suture, needle, angioplasty device, artificial joint heart valve, neurological stimulators or drug pump, stents with biofilm, sirolimus-eluting stent, paclitaxel-eluting stent and device reducing thrombosis. Repellent coating such as calixarenes and resorcarene can be used.

Description

Coated Medical Devices The present invention relates to implantable

medical devices, such as stents, that have a biorepellant coating that is both oleophobic and hydrophobic, said coated S devices being useful for reducing thrombosis associated with such implants.

Every day, thousands of people suffer heart attacks caused by underlying coronary artery disease. Coronary artery disease (CAD) is mankind's most widespread and lethal disease, affecting over 14 million Americans. Of these, one million will suffer a subsequent acute myocardial infarction (AMI) each year, with a five year mortality of nearly 30%.

CAD is a disease of the coronary arteries, in which the vessels supplying blood to the heart muscle become narrowed by atherosclerotic plaques. This stenosis restricts blood flow and, in severe cases, the oxygen delivery to cardiac tissue, causing myocardial ischemia and anginal pain. Total occlusion of these arteries, caused by plaque rupture, is the underlying cause of a heart attack, and results in permanent tissue death: an AMI.

A common and safe coronary intervention carried out to prevent heart attacks or to relieve the blockage associated with AMI is to thread a catheter into the blocked artery and expand the channel with an inflatable balloon. A stent, consisting of a wire mesh tube, is then placed in the artery to hold the artery open and to restore adequate blood flow. The arterial wall heals over the stent, incorporating it as a permanent solution, but this process fails in up to 1/3 of patients as the artery wall overdevelops as a result of neointimal proliferation (restenosis). Furthermore, clots can form on or around the stent itself due to inflammation and increased platelet adhesion, leading to abrupt occlusion of the open vessel through thrombosis. Thus, it is not surprising that with over 500,000 stent procedures a year, restenosis and thrombosis are major health and cost burdens.

Drug-eluting stents, e.g. CypherTM, are used as one solution to the problem of neointimal growth. A bare-metal stent is coated with an inert polymer that slowly releases embedded deposits of sirolimus, an antibiotic with immunosuppressive properties, at the artery wall. This drug slows the multiplication and growth of epithefial cells, reducing the thickness of the lumen as it heals. Clinical trials have shown that the two existent drug eluting stents, CypherTM and TaxusTM, have achieved a decrease of up to 80% in revascularization procedures needed to relieve restenosis. However, these drugs also make the vessels more prone to processes that lead to the formation of a blood clot. Administration of anti-platelet and anticoagulant drugs may prevent platelet and fibrinogen interaction with the endothelial wall while it heals, but it raises the risk of haemorrhage. Thus, up to 2% of patients receiving drug-eluting stents may suffer thrombosis, a potentially fatal complication, which in addition to the risk of haemorrhage associated with current therapies, constituting a major concern for interventional cardiologists.

Recent attempts to address the issues of protein adhesion and thrombus formation have centred on the possibility of using another drug, such as heparin, instead of and possibly in addition to the current immunosuppressive drug in the stent coating to directly prevent thrombosis. However, hepann exerts its effect against circulating blood components, not on cells in adjacent tissue. Thus a strategy of slow release from the stent itself would not result in therapeutic quantities accumulating in the blood flowing through the coronary arteries. Secondly, if the rate of release is increased to achieve therapeutic concentrations, then the amount of drug in the stent is exhausted before the healing process is complete. Late-stage thrombosis would thus remain a problem. Thirdly, the spread of antiplatelet agents beyond the immediate vicinity of the stent could pose a risk of haemorrhage to tissues of the heartand lungs.

There is a need, therefore, for an alternative coating that provides a solution to the problems of foreign body reaction and irritation leading to excessive inflammation, and subsequent thrombus formation. Ideally, such a coating will be: 1. Biologically inert: -will not exacerbate inflammation -will not carry risk of side-effects.

2. Durable: -will remain part of the stent surface, effective for duration of the stents life-time.

3. Thin-film coating: -will form a smooth monolayer over the stent, decreasing turbulence caused by surface roughness, a factor which has been implicated in coronary thrombosis.

4. Non-pharmacologic: -will not incur any drug-drug interactions with immunosuppressive already coupled to the stent.

-will not require control of elution rates -will not require characterization or testing for drug stability, availability, release, or degradation.

5. Localized effect: -can be applied preferentially to the luminal side of the stent, facing the blood stream, while the endothelial side could still be coated with the conventional drug-eluting combination, achieving an optimal combination.

It is therefore an object of the present invention to provide a stent which is less irritating and repels protein and thrombotic deposits and has long-term benefits for patients, physicians and payers.

The present invention accordingly provides an implantable medical device having a coating comprising an outer surface that is both oleophobic and hydrophobic. Such a coating will be able to resist adhesion platelets and protein factors involved in clotting and subsequent thrombus formation, making stents safer as well as decreasing the need for high doses of antiplatelet drugs.

Preferably, with such a stent, the luminal side comprises a coating comprising an outer surface that is both oleophobic and hydrophobic and the endothelial side is bare metal or is coated with a drug-eluting composition.

The inner surface of said coating may be hydrophilic or be modified so as to preferentially bind to the substrate. The coating would preferably form a monolayer over the device, thus providing a smooth surface that would decrease turbulence.

In order to provide an outer surface that is both oleophobic and hydrophobic, said coating may comprises long chain hydrocarbon or fluorocarbon groups, or long chain polyether groups, each having from 1 to 18 carbon atoms in the chain. The hydrocarbon or fluorocarbon groups preferably have from 5 to 15 carbon atoms in the chain. Preferably, the hydrocarbon and fluorocarbon groups are saturated or unsaturated alkyl and fluoroalkyl groups, respectively.

The invention encompasses any implantable medical device and in particular covers a medical device which is a stent, catheter, vascular graft, cardiac pacer lead, heart diaphragm, suture, needle, angioplasty device, artificial joint, heart valve, neurological stimulator or drug pump. Stents are the most preferred medical devices to which the invention is directed.

In a preferred embodiment of the invention, the oleophobic and hydrophobic coating is applied to the luminal side of the stent only. In another preferred embodiment the endothelial side of the stent is coated with a drug-eluting composition.

Any drug may be used and is preferably an immunosuppressant, antibiotic or an antiplatelet or anticoagulant agent. Alternatively, the drug etuting composition may comprise a stem-cell eluting composition. Most preferred drugs for coating the stent are sirolimus or paclitaxel.

Accordingly the invention provides a stent wherein the luminal side comprises a coating comprising an outer surface that is both oleophobic and hydrophobic and the endothelial side is bare metal or is coated or impregnated with a drug-eluting composition.

In another preferred embodiment the entire stent is coated with a coating comprising an outer surface that is both oleophobic and hydrophobic wherein the endothelial side of the stent is additionally coated or impregnated with a drug-eluting composition.

According to a preferred embodiment of the invention the coating comprises a calixarene.

Calixarenes are macrocyclic molecules based on the hydroxyalkyation product of a phenol and an aldehyde and whose general structure is that of a molecular bowl on legs with the rim of the bowl lined by hydroxyl groups and the legs consisting of long-chain alkyl groups. A detailed review of the different types of calixarenes and their methods of manufacture is given by Bohmer, Angew. Chem. lnt. Ed. EngI. 1995, 34, 713-745. The surface properties of the calixarenes may be suitably modified to impart the desired properties by altering the substituents on either the nm or the legs.

There are three main types of calixarene, prepared respectively from phenols, from resorcinols (resorcarene) and from pyrogaUols and aldehydes. The present invention is applicable to all these types of calixarenes, and encompasses devices having a coating derived from any one of them. Preferably, the invention covers a device wherein the calixarene is a resorcarene.

In a preferred embodiment the calixarene, preferably a resorcarene, provides a surface that is both oleophobic and hydrophobic, said calixarene comprising long chain hydrocarbon or fluorocarbon groups, or long chain polyether groups, each having from 1 to 18 carbon atoms in the chain. The hydrocarbon or fluorocarbon groups preferably have from 5 to 15 carbon atoms in the chain. Preferably, the hydrocarbon and fluorocarbon groups are saturated or unsaturated alkyl and fluoroalkyl groups, respectively.

In a preferred embodiment of the invention, the medical device has a coating which comprises a resorcarene of formula (I) x

R K y V /\ \/

Y (R I \ (I)

wherein X is hydrogen, C1-C4 alkyl, NH2, NH(C1-C4 alkyl), or N(C1-C4 alkyl)2; Y is OH or OCH2COOR', where R' is C,-C4 alkyl; R is a C5-C15 fluoro-substituted alkyl group; n is 1 or 3, and wherein each X, Y, R' and R group can be the same or different.

Preferably, the devices are coated with a resorcarene of formula (1) wherein X is hydrogen and R is-CH2C8F17.

The calixarenes of the invention may be suitably modified in order to provide an outer surface that is both oleophobic and hydrophobic, said modification may comprise incorporation of long chain hydrocarbon or fluorocarbon groups, or long chain polyether groups, each having from I to 18 carbon atoms in the chain. The hydrocarbon or fluorocarbon groups preferably have from 5 to 15 carbon atoms in the chain. Preferably, the hydrocarbon and fluorocarbon groups are saturated or unsaturated alkyl and fluoroalkyl groups, respectively.

Methods for the preparation of the resorcarene of formula (I) and processes for coating materials are disclosed in WO 97/39077 and at http:I/www.rsc.org/pdf/mcgfshefcotes.pdf. Other suitable methods for coating medical devices such as stents are known to those skilled in the art and include, e.g. methods described in WO 2005/112570, US 6702850, US 6602287, US 5053048, US 7070798 and US 2002/0102405. The surface of the medical devices may also be subject to treatment to modify the surface properties prior to coating such as disclosed in US 4445998 and Kim, Surface and Coatings Technology, 171, 2003, 312-316.

Claims (1)

  1. Claims 1. An implantable medical device having a coating comprising an
    outer surface that is both oleophobic and hydrophobic.
    2. A device according to claim 1 wherein the inner surface of the coating is hyd rophil ic.
    3. A device according to either claim 1 or claim 2 wherein the coating forms a monolayer over the device.
    5. A device according to any one of claims 1 to 3 wherein the outer surface of the coating comprises long chain hydrocarbon or fluorocarbon groups, or long chain polyether groups, each having from 1 to 18 carbon atoms in the chain.
    6. A device according to claim 5 wherein the hydrocarbon and fluorocarbon groups are saturated or unsaturated alkyl and fluoroalkyl groups, respectively.
    7. A device according to any one of claims 1 to 6 which is a stent, catheter, vascular graft, cardiac pacer lead, heart diaphragm, suture, needle, angioplasty device, artificial joint, heart valve, neurological stimulator or drug pump.
    8. A device according to claim 7 which is a stent.
    9. A stent according to claim 8 wherein the oleophobic and hydrophobic coating is applied to the luminal side of the stent only.
    10. A stent according to either claim 8 or claim 9 wherein the endothelial side is coated with a drug-eluting composition.
    11. A stent according to claim 10 wherein the drug is an immunosuppressant, antibiotic or an antiplatelet or anticoagulant agent, or the drug-eluting composition is a stem-cell eluting composition.
    12. A stent according to claim 11 wherein the drug is sirolimus or paclitaxel.
    13. A stent wherein the luminal side comprises a coating comprising an outer surface that is both oleophobic and hydrophobic and the endothelial side is bare metal or is coated with a drug-eluting composition.
    14. A device according to any one of claims I to 13 wherein the coating comprises a calixarene.
    15. A device according to claim 14 wherein the calixarene is derived from phenols, from resorcinols (resorcarene) and from pyrogallols and aldehydes.
    16. A device according to claim 15 wherein the calixarene is a resorcarene.
    17. A device according to claim 16 wherein the resorcarene is a compound of formula (I)
    N
    R R /_\
    Y \ x (I)
    wherein X is hydrogen, C1-C4 alkyl, NH2, NH(C,-C4 alkyl), or N(C1-C4 alky))2; V is OH or OCH2COOR', where R' is C1-C4 alkyl; R is a C5-C15 fluoro-substituted alkyl group; n is I or 3, and wherein each X, Y, R' and R group can be the same or different.
    18. A device according to claim 17 wherein X is hydrogen and R is-CH2C8F17.
GB0706532A 2007-04-04 2007-04-04 Coated medical devices Active GB2448153B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0706532A GB2448153B (en) 2007-04-04 2007-04-04 Coated medical devices

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0706532A GB2448153B (en) 2007-04-04 2007-04-04 Coated medical devices

Publications (3)

Publication Number Publication Date
GB0706532D0 GB0706532D0 (en) 2007-05-09
GB2448153A true true GB2448153A (en) 2008-10-08
GB2448153B GB2448153B (en) 2011-12-28

Family

ID=38050802

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0706532A Active GB2448153B (en) 2007-04-04 2007-04-04 Coated medical devices

Country Status (1)

Country Link
GB (1) GB2448153B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2498356A (en) * 2012-01-11 2013-07-17 Camstent Ltd Derivatised calixarenes as coatings for implantable medical devices

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105596128A (en) * 2016-01-23 2016-05-25 万平 Duodenum internal wrapping film

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050221072A1 (en) * 2003-04-17 2005-10-06 Nanosys, Inc. Medical device applications of nanostructured surfaces

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2294872A1 (en) * 1997-06-24 1998-12-30 Schering Aktiengesellschaft Stents that are coated with fluoroalkyl groups, processes for their production and their use for restenosis prophylaxis
US6251136B1 (en) * 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
EP1381394A2 (en) * 2001-04-17 2004-01-21 Celltran Limited Biomaterials comprising a melanocyte stimulating hormone (msh), and method of forming
ES2635270T3 (en) * 2003-12-12 2017-10-03 C.R.Bard, Inc. Implantable medical devices fluoropolymer coatings and coating methods thereof
EP1808056B1 (en) * 2004-11-05 2015-08-26 Dow Corning Ireland Limited Plasma process

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050221072A1 (en) * 2003-04-17 2005-10-06 Nanosys, Inc. Medical device applications of nanostructured surfaces

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2498356A (en) * 2012-01-11 2013-07-17 Camstent Ltd Derivatised calixarenes as coatings for implantable medical devices
WO2013104916A2 (en) 2012-01-11 2013-07-18 Camstent Limited Medical devices, coatings and compounds
WO2013104916A3 (en) * 2012-01-11 2013-10-17 Camstent Limited Medical devices, coatings and compounds
GB2498356B (en) * 2012-01-11 2016-09-07 Camstent Ltd Calixarene-derived coatings for implantable medical devices

Also Published As

Publication number Publication date Type
GB2448153B (en) 2011-12-28 grant
GB0706532D0 (en) 2007-05-09 grant

Similar Documents

Publication Publication Date Title
Hårdhammar et al. Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries
US6918929B2 (en) Drug-polymer coated stent with pegylated styrenic block copolymers
US7396538B2 (en) Apparatus and method for delivery of mitomycin through an eluting biocompatible implantable medical device
US7144419B2 (en) Drug-polymer coated stent with blended phenoxy and styrenic block copolymers
US6306166B1 (en) Loading and release of water-insoluble drugs
US20080132992A1 (en) Coated implantable medical device
US5824049A (en) Coated implantable medical device
US20090098176A1 (en) Medical devices with triggerable bioadhesive material
US20070050010A1 (en) Coated implantable medical device
US20070038289A1 (en) Stent to be placed in vivo
US20080188836A1 (en) Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US6096070A (en) Coated implantable medical device
US6730064B2 (en) Coated implantable medical device
US6589546B2 (en) Polymeric coatings for controlled delivery of active agents
US20010007083A1 (en) Device and active component for inhibiting formation of thrombus-inflammatory cell matrix
US20030216806A1 (en) Stent
US7176261B2 (en) Angiotensin-(1-7) eluting polymer-coated medical device to reduce restenosis and improve endothelial cell function
US20090030494A1 (en) Method and devices for treatment of vulnerable (unstable) and/or stable atherosclerotic plaque by disrupting pathologic vasa vasorum of the atherosclerotic plaque
US20090186068A1 (en) Atomic plasma deposited coatings for drug release
US20060127442A1 (en) Use of supercritical fluids to incorporate biologically active agents into nanoporous medical articles
US7550005B2 (en) Coated implantable medical device
US20050180919A1 (en) Stent with radiopaque and encapsulant coatings
EP1604697A1 (en) Implantable device
US6530951B1 (en) Silver implantable medical device
US20080208313A1 (en) Drug Coated Stent With Magnesium Topcoat